Healios K.K (TYO:4593) has agreed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on the clinical data package for conditional approval of MultiStem for Acute Respiratory Distress Syndrome, according to a Wednesday filing with the Tokyo Stock Exchange.

The approval will be based on Phase 2 trial results, with future Phase 3 data from the US as confirmatory support.

MultiStem is a regenerative medicine targeting ARDS, ischemic stroke, and trauma, and has received FDA Fast Track and RMAT designations.

Price (JPY): $200.00, Change: $-1.0, Percent Change: -0.50%